TULIVIN LABORATORIES LIMITED

Company Registration Number:
NI027128 (Northern Ireland)

Unaudited statutory accounts for the year ended 30 June 2024

Period of accounts

Start date: 1 July 2023

End date: 30 June 2024

TULIVIN LABORATORIES LIMITED

Contents of the Financial Statements

for the Period Ended 30 June 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

TULIVIN LABORATORIES LIMITED

Directors' report period ended 30 June 2024

The directors present their report with the financial statements of the company for the period ended 30 June 2024

Principal activities of the company

The principal activity of the company is to carry on the business of importers, exporters, manufacturers, retailers, dealers and distributors in veterinary supplies of all kinds.

Political and charitable donations

During the year the company has made no political contributions



Directors

The directors shown below have held office during the whole of the period from
1 July 2023 to 30 June 2024

George Crowe
Brendan Crowe


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
14 November 2025

And signed on behalf of the board by:
Name: George Crowe
Status: Director

TULIVIN LABORATORIES LIMITED

Profit And Loss Account

for the Period Ended 30 June 2024

2024 2023


£

£
Turnover: 1,125,487 959,669
Cost of sales: ( 977,087 ) ( 895,538 )
Gross profit(or loss): 148,400 64,131
Administrative expenses: ( 30,153 ) ( 27,831 )
Operating profit(or loss): 118,247 36,300
Interest receivable and similar income: 1,345
Interest payable and similar charges: ( 1,332 )
Profit(or loss) before tax: 116,915 37,645
Tax: ( 32,235 ) ( 7,199 )
Profit(or loss) for the financial year: 84,680 30,446

TULIVIN LABORATORIES LIMITED

Balance sheet

As at 30 June 2024

Notes 2024 2023


£

£
Current assets
Stocks: 4 6,949 11,243
Debtors: 5 266,429 85,730
Cash at bank and in hand: 618,526 544,447
Total current assets: 891,904 641,420
Creditors: amounts falling due within one year: 6 ( 398,247 ) ( 287,349 )
Net current assets (liabilities): 493,657 354,071
Total assets less current liabilities: 493,657 408,977
Total net assets (liabilities): 493,657 408,977
Capital and reserves
Called up share capital: 100 100
Profit and loss account: 493,557 408,877
Total Shareholders' funds: 493,657 408,977

The notes form part of these financial statements

TULIVIN LABORATORIES LIMITED

Balance sheet statements

For the year ending 30 June 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 14 November 2025
and signed on behalf of the board by:

Name: George Crowe
Status: Director

The notes form part of these financial statements

TULIVIN LABORATORIES LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

    Tangible fixed assets depreciation policy

    Tangible assets Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

    Other accounting policies

    Basis of preparation The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss. The financial statements are prepared in sterling, which is the functional currency of the entity. Cash flow statement The company has availed of the exemption in FRS 102 Section 1A from the requirement to prepare a Statement of Cash Flows because it is classified as a small company. Taxation The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference. Foreign currencies Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to profit or loss. Depreciation Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows: Computer Equipment - 33% If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates. Fixed asset investments Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss. Impairment A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. Stocks Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition. Financial instruments A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship. Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

TULIVIN LABORATORIES LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 0 0

TULIVIN LABORATORIES LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

3. Fixed assets investments note

8. Investments Listed investments Total Cost £ £ At 1 July 2023 54,906 54,906 Disposals (58,468) (58,468) Other movements 3,562 3,562 At 30 June 2024 0 0 - Impairment At 1 July 2023 and 30 June 2024 0 0 Carrying amount At 30 June 2024 0 0 At 30 June 2023 54,906 54,906

TULIVIN LABORATORIES LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

4. Stocks

2024 2023
£ £
Stocks 6,949 11,243
Total 6,949 11,243

TULIVIN LABORATORIES LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

5. Debtors

2024 2023
£ £
Trade debtors 197,529 85,730
Other debtors 68,900
Total 266,429 85,730

10. Debtors 2024 2023 £ £ Trade debtors 197,529 85,730 Deferred tax asset (note 13) 17,386 0 Directors loan accounts 51,514 0 266,429 85,730 13. Deferred tax The deferred tax included in the statement of financial position is as follows: 2024 2023 £ £ Included in debtors (note 10) 17,386 0 The deferred tax account consists of the tax effect of timing differences in respect of: 2024 2023 £ £ Reclaimable tax paid on Loan to Participator 17,386 0

TULIVIN LABORATORIES LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

6. Creditors: amounts falling due within one year note

2024 2023
£ £
Trade creditors 285,782 226,999
Taxation and social security 99,199 55,214
Accruals and deferred income 13,266 3,076
Other creditors 2,060
Total 398,247 287,349

TULIVIN LABORATORIES LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

7. Loans to directors

Name of director receiving advance or credit: Brendan Crowe
Description of the transaction:
Advances to Director
£
Balance at 30 June 2023
Advances or credits made: 51,514
Advances or credits repaid:
Balance at 30 June 2024 51,514